title: Variability in Expression of CYP3A5 in Human Fetal Liver.
abstract: Members of the cytochrome P450 3A (CYP3A) subfamily of drug metabolizing enzymes exhibit developmental changes in expression in human liver characterized by a transition between CYP3A7 and CYP3A4 over the first few years of life. In contrast, the developmental expression of CYP3A5 is less well understood due to polymorphic expression of the enzyme in human tissues as a result of the prevalence of the CYP3A5*3 allele, which leads to alternative splicing. We further explored the expression of CYP3A5 and the impact of alternative splicing on the variability of CYP3A5 functional activity in a large bank of human prenatal liver samples (7 to 32 weeks of age postconception). The expression of normally spliced CYP3A5 mRNA in all human fetal liver samples varied 235-fold whereas CYP3A5 SV1 mRNA was only detected in fetal liver samples with at least one CYP3A5*3 allele. Formation of 1'-OH midazolam (MDZ) varied 79-fold, and the ratio of 1'-OH MDZ to 4-OH MDZ varied 8-fold and depended on the presence or absence of the CYP3A5*3 allele. Formation of 4-OH MDZ was significantly associated with 1'-OH MDZ (r(2) = 0.76, P < 0.0001) but varied (36-fold) independently of CYP3A5 genotype or expression. The substantial interindividual variability that remains even after stratification for CYP3A5 genotype suggests that factors such as environmental exposure and epigenetic alterations act in addition to genetic variation to contribute to the variability of CYP3A5 expression in human prenatal liver.
authors.affiliation: Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.) cvyhlidal@cmh.edu.
authors.forename: Carrie A
authors.initials: CA
authors.lastname: Vyhlidal
authors.affiliation: Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.).
authors.forename: Robin E
authors.initials: RE
authors.lastname: Pearce
authors.affiliation: Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.).
authors.forename: Roger
authors.initials: R
authors.lastname: Gaedigk
authors.affiliation: Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.).
authors.forename: Justina C
authors.initials: JC
authors.lastname: Calamia
authors.affiliation: Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.).
authors.forename: Diana L
authors.initials: DL
authors.lastname: Shuster
authors.affiliation: Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.).
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Thummel
authors.affiliation: Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri (C.A.V., R.E.P., R.G., J.S.L.); Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington (J.C.C., D.L.S., K.E.T.).
authors.forename: J Steven
authors.initials: JS
authors.lastname: Leeder
mesh_terms: D000328:Adult; D000483:Alleles; D001711:Biotransformation; D051544:Cytochrome P-450 CYP3A / Q000096:biosynthesis* / Q000235:genetics*; D044127:Epigenesis, Genetic; D005260:Female; D005333:Fetus / Q000201:enzymology*; D014644:Genetic Variation; D005838:Genotype; D005865:Gestational Age; D006801:Humans; D006900:Hydroxylation; D008099:Liver / Q000201:enzymology*; D008862:Microsomes, Liver / Q000201:enzymology; D008874:Midazolam / Q000493:pharmacokinetics; D011247:Pregnancy; D012326:RNA Splicing; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics
chemical_list: D012333:RNA, Messenger; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D008874:Midazolam